Stock Scorecard



Stock Summary for Evogene Ltd (EVGN) - $1.06 as of 12/3/2025 10:53:09 PM EST

Total Score

9 out of 30

Safety Score

15 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for EVGN

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for EVGN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for EVGN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for EVGN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for EVGN (15 out of 100)

Stock Price Rating (Max of 10) 2
Historical Stock Price Rating (Max of 10) 6
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 2
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 3
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for EVGN

Evogene Declares The Sale Of Lavie Bio’s Activity To ICL Completed 8/24/2025 12:00:00 AM
Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud 6/10/2025 7:00:00 AM
Evogene: Q4 Earnings Snapshot 12/31/2024 11:59:00 PM
Gene-editing breakthrough in giant river prawns 10/10/2024 8:29:00 AM
AgPlenus Appoints Dr. Dan Jacob Gelvan as Chief Executive Officer 2/22/2024 12:00:00 AM
Syngenta Crop Protection and Lavie Bio Forge Collaboration to Develop Biological Insecticidal Solutions 2/22/2024 12:00:00 AM
Biomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology Drug 1/17/2024 12:00:00 AM
Evogene Reports Second Quarter 2023 Financial Results 8/18/2023 12:00:00 AM
Casterra to supply castor feedstock for biofuel production 1/27/2023 12:00:00 AM
Biomica & Rambam Health Care Campus Sign Agreement for Clinical Trial of Biomica's Microbiome-Based Immuno-Oncology Drug 10/27/2021 3:15:00 PM

Financial Details for EVGN

Company Overview

Ticker EVGN
Company Name Evogene Ltd
Country USA
Description Evogene Ltd. is a pioneering computational biology company based in Rehovot, Israel, specializing in the development of sustainable agricultural solutions through advanced data-driven methodologies. Utilizing its proprietary technology platforms, Evogene focuses on biotechnology applications that enhance crop productivity and resilience, ultimately addressing the challenges of food security in a changing climate. The company's innovative approach leverages genomic data to discover and optimize traits in various agricultural sectors, positioning Evogene as a key player in the ag-tech industry. With growing global demand for efficient agricultural practices, the company's solutions are critical in promoting sustainable farming and improving resource management.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 9/30/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 1.06
Price 4 Years Ago 16.40
Last Day Price Updated 12/3/2025 10:53:09 PM EST
Last Day Volume 52,086
Average Daily Volume 54,552
52-Week High 2.42
52-Week Low 0.95
Last Price to 52 Week Low 11.58%

Valuation Measures

Trailing PE N/A
Industry PE 43.11
Sector PE 88.06
5-Year Average PE -10.44
Free Cash Flow Ratio 1.63
Industry Free Cash Flow Ratio 13.81
Sector Free Cash Flow Ratio 28.78
Current Ratio Most Recent Quarter 4.92
Total Cash Per Share 0.65
Book Value Per Share Most Recent Quarter 0.13
Price to Book Ratio 7.86
Industry Price to Book Ratio 33.69
Sector Price to Book Ratio 33.12
Price to Sales Ratio Twelve Trailing Months 1.20
Industry Price to Sales Ratio Twelve Trailing Months 31.75
Sector Price to Sales Ratio Twelve Trailing Months 15.97
Analyst Buy Ratings 1
Analyst Strong Buy Ratings 0

Share Statistics

Total Shares Outstanding 8,716,400
Market Capitalization 9,239,384
Institutional Ownership 1.88%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 30.96%
Reported EPS 12 Trailing Months -1.13
Reported EPS Past Year -1.31
Reported EPS Prior Year -2.39
Net Income Twelve Trailing Months -2,748,000
Net Income Past Year -16,485,000
Net Income Prior Year -23,879,000
Quarterly Revenue Growth YOY -82.60%
5-Year Revenue Growth 62.42%
Operating Margin Twelve Trailing Months -873.00%

Balance Sheet

Total Cash Most Recent Quarter 5,626,000
Total Cash Past Year 15,301,000
Total Cash Prior Year 20,772,000
Net Cash Position Most Recent Quarter -4,766,000
Net Cash Position Past Year 4,933,000
Long Term Debt Past Year 10,368,000
Long Term Debt Prior Year 10,368,000
Total Debt Most Recent Quarter 10,392,000
Equity to Debt Ratio Past Year -0.16
Equity to Debt Ratio Most Recent Quarter 0.10
Total Stockholder Equity Past Year -1,451,000
Total Stockholder Equity Prior Year 12,053,000
Total Stockholder Equity Most Recent Quarter 1,142,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -22,155,948
Free Cash Flow Per Share Twelve Trailing Months -2.54
Free Cash Flow Past Year -20,326,000
Free Cash Flow Prior Year -22,362,000

Options

Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.05
MACD Signal -0.03
20-Day Bollinger Lower Band 1.05
20-Day Bollinger Middle Band 1.21
20-Day Bollinger Upper Band 1.37
Beta 1.57
RSI 38.74
50-Day SMA 4.69
150-Day SMA 0.00
200-Day SMA 5.85

System

Modified 12/3/2025 10:53:11 PM EST